BioLAGO and BIOPRO to start new diagnostics project - 07/07/2016 DiagNeeds: translating clinical requirements into new products (Lake Constance/Stuttgart) – BioLAGO e.V. and BIOPRO Baden-Württemberg GmbH are working together on the “DiagNeeds” project to bring hospitals and medical professionals closer to diagnostics providers in order to facilitate the development of new diagnostic procedures. There will be special focus on topics that are currently of major interest in the field of diagnostics, including liquid biopsies, companion diagnostics, point-of-care diagnostics…https://www.gesundheitsindustrie-bw.de/en/article/press-release/diagneeds-klinik-bedarfe-in-neue-produkte-uebersetzen
Overview Diagnostics The latest articles, press releases and dossiers on diagnostics in Baden-Württemberghttps://www.gesundheitsindustrie-bw.de/en/article/diagnostics
Press release - 24/10/2011 Curetis AG Opens Unyvero™ Cartridge Production Facility Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, announced the opening of its state-of-the-art production facility for disposable Unyvero™ cartridges in Bodelshausen (near Tuebingen, Germany).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-opens-unyvero-cartridge-production-facility
Company profile: medicalvalues GmbH - 05/05/2022 medicalvalues – best possible diagnostics thanks to AI The Karlsruhe-based start-up medicalvalues GmbH wants to use its platform to bring together different clinical data sets and thus enable comprehensive medical diagnostics. Artificial intelligence featuring innovative diagnostic algorithms is used to evaluate the data and generate new insights for laboratories and hospitals.https://www.gesundheitsindustrie-bw.de/en/article/news/medicalvalues-best-possible-diagnostics-thanks-ai
Press release - 04/11/2010 LifeCodexx Appoints Head of Commercial Operations Dr. Martin Burow, a proven expert in the field of prenatal diagnostics, has joined the LifeCodexx team as Head of Commercial Operations.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lifecodexx-appoints-head-of-commercial-operations
Press release - 07/12/2009 Curetis AG - € 18.5 million Series A Financing Round closed A consortium of leading life-science venture capital funds invests € 18.5 million in the German medical diagnostics company Curetis AG. This financing will enable Curetis to complete development of its innovative diagnostic products through to market entry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-18-5-million-series-a-financing-round-closed
Press release - 25/11/2010 BD Diagnostics and Lonza Collaborate BD Diagnostics, a segment of BD (Becton, Dickinson and Company), and Lonza Group Ltd announced today that they have entered into an exclusive licensing and collaboration agreement for Lonza to commercialize its microCompass™ molecular assays on the BD MAX™ System.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bd-diagnostics-and-lonza-collaborate
Article - 12/03/2012 Q-bios provides client-specific biotechnology services Q-bios GmbH, a spin-off from the Mannheim University of Applied Sciences, is a biotechnology company that provides services related to the production and purification of diagnostic and therapeutic proteins as well as the development and amplification of suitable cell lines. The company offers its services, which are based on state-of-the-art technologies, to clients from the biotechnology, diagnostic and pharmaceutical industries.https://www.gesundheitsindustrie-bw.de/en/article/news/q-bios-provides-client-specific-biotechnology-services
Dossier - 10/03/2014 Cancer therapy and cancer diagnostics Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
Article - 04/04/2011 Technical innovations for better diagnostics The quantitative detection of DNA single-strand breaks is of great importance for many areas of biomedical research and diagnostics. The Fluorescence-detected Alkaline DNA Unwinding FADU assay assists in the investigation of mechanisms of DNA damage and repair following DNA strand breaks upon exposure to chemicals. Prof. Alexander Bürkle and his team at the University of Konstanz have automated and optimised the original FADU assay which was…https://www.gesundheitsindustrie-bw.de/en/article/news/technical-innovations-for-better-diagnostics
Article - 20/10/2014 QIAGEN Lake Constance – pocket-sized laboratories for the efficient identification of pathogens Quick, simple and decentralized – this is how QIAGEN Lake Constance GmbH envisages diagnostics applications in the future. The Stockach-based QIAGEN subsidiary develops test systems for point-of-need diagnostics, i.e. tests that can be carried out in close proximity to the sample collection point, for example in GP surgeries. They enable the rapid identification of pathogens, and as a result the timely initiation of suitable treatment.https://www.gesundheitsindustrie-bw.de/en/article/news/qiagen-lake-constance-pocket-sized-laboratories-for-the-efficient-identification-of-pathogens
Event - 12/10/2022 - 13/10/2022 Diagnostics-4-Future Conference 2022 Konstanz, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/diagnostics-4-future-conference-2022
Press release - 19/05/2011 Curetis AG successfully increases Series A financing round to EUR 24.5 million Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series A financing, bringing the total size of the round to € 24.5 million. CD-Venture joined the funding as a new investor, while all of Curetis' existing VC investors participated in the round. Several private investors also continued to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-successfully-increases-series-a-financing-round-to-eur-24-5-million
Press release - 26/04/2008 Curetis AG - Compact weapon against tuberculosis In conjunction with reference laboratories of the World Health Organization WHO medtech company Curetis AG is developing new technologies and products that identify the pathogens of infectious diseases such as tuberculosis and their resistance. The solutions are impressive. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-compact-weapon-against-tuberculosis
Press release - 14/10/2009 mtm laboratories Extends Series C Financing Round by EUR 7 Million Bringing Total to EUR 39 Million (USD 57 Million) mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, announced on 14th October the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company’s last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/mtm-laboratories-extends-series-c-financing-round-by-eur-7-million-bringing-total-to-eur-39-million
Press release - 04/02/2020 CeGaT Brings New Dimension to Exome Diagnostics CeGaT aims to solve all genetically-caused cases of disease to help physicians state a diagnosis. To pursue this goal, CeGaT incorporated its long-term expertise and latest scientific knowledge in an innovative diagnostic tool: CeGaT Exome Xtra is the most powerful genetic diagnostic option for patients with complex, unspecific, and rare diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cegat-ermoeglicht-neue-dimension-der-exom-diagnostik
Article - 14/04/2016 Rapid and unambiguous detection of infection in a miniature laboratory In cooperation with industrial partners, researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have spent many years developing innovative diagnostic tools for use in infection biology. Among these are microsystems that combine complete test procedures on a “lab-on-a-chip” (LOC) and enable simultaneous analysis of several thousand parameters relatively quickly and with little effort. The scientists…https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-and-unambiguous-detection-of-infection-in-a-miniature-laboratory
Article - 10/05/2010 CeGaT: DNA and RNA sequencing specialist Sequencing service providers are facing new challenges due to the enormous technological progress made in this field. The market requires technically feasible solutions reliable and rapid sequence analyses in which entire genomes can be analysed within a couple of days or weeks. This can only be achieved with state-of-the-art high-throughput technologies. Tübingen-based CeGaT GmbH has been offering DNA and RNA sequencing using state-of-the-art…https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-dna-and-rna-sequencing-specialist
Press release - 12/03/2010 mtm laboratories announces the European launch of CINtec® PLUS mtm laboratories, a privately held diagnostics company from Heidelberg, Germany, announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mtm-laboratories-announces-the-european-launch-of-cintec-plus
Press release - 20/07/2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer Roche announced on July 19th that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. mtm is a global leader in developing in vitro diagnostics with a focus on early detection and diagnosis of cervical cancer, the largest early detection market in oncology. mtm will become part of Roche’s Tissue Diagnostics (Ventana Medical Systems, Inc.) business…https://www.gesundheitsindustrie-bw.de/en/article/press-release/roche-acquires-mtm-laboratories-ag-expanding-offering-in-cervical-cancer
Article - 13/01/2014 DIARECT AG – development and production of immunodiagnostics components Founded by Dr. Heinz Haubruck and Prof. Dr. Bodo Liedvogel in 1998, the biotechnology company DIARECT AG (DIAgnostic by RECombinant Technology) from Freiburg sells tried and tested and new products. The company produces proteins, nucleoproteins and assay components for the diagnostics sector. These products enable the reliable identification of autoimmune disorders and infectious diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/diarect-ag-development-and-production-of-immunodiagnostics-components
Press release - 08/01/2009 ILM – Molecular cytogenetic diagnostics The ILM used multicolour fluorescence in-situ hybridisation for the detection of chromosomal changes in the vein tissue of patients suffering from recurrent varicosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-molecular-cytogenetic-diagnostics
Article - 30/08/2010 Diagnostics for the early detection of cervical cancer The Pap test is regarded as the most successful test for cancer ever, and has saved the lives of many women. However, the test is associated with several weaknesses. The Heidelberg-based in vitro diagnostics company mtm laboratories AG develops and commercialises highly sensitive and highly specific immunochemical tests that provide greater reliability. These tests have the potential to revolutionise the early detection of cervical cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/diagnostics-for-the-early-detection-of-cervical-cancer
Biotech start-up from Frickenhausen develops chewing gum as test system for bacteria - 19/12/2019 A medical connoisseur – the tongue as a sensor for infections The start-up 3a-diagnostics GmbH from Frickenhausen is developing a gum that can be used both in doctors’ surgeries and at home as a quick and easy diagnostic aid. The sensor in this case is the human tongue. If bacteria are present – due to an inflammation of the teeth or tonsils, for instance – chewing produces a bitter taste and the doctor can quickly initiate the appropriate treatment. https://www.gesundheitsindustrie-bw.de/en/article/press-release/medizinischer-feinschmecker-die-zunge-als-sensor-fuer-infektionen
Article - 07/04/2014 BIPSO GmbH – modern contrast agents for the entire world BIPSO GmbH, based in Singen, Germany, has been manufacturing contrast agents for applications in modern medical diagnostics since 2011. BIPSO is part of the Bracco Imaging Group, which is one of the world’s leading specialists in the diagnostic imaging business, and produces imaging agents mainly for Bracco’s sales organisations. The company has recently invested in the expansion of its manufacturing site in Singen with the goal of consolidating…https://www.gesundheitsindustrie-bw.de/en/article/news/bipso-gmbh-modern-contrast-agents-for-the-entire-world